T Cell Lymphoma
Understanding Lymphoma: B-cell vs. T-cell
Lymphomas are broadly categorized into Hodgkin and non-Hodgkin lymphomas, with the latter further divided into B-cell and T-cell lymphomas. B-cell lymphomas, being more prevalent, benefit from extensive research and numerous treatment options. However, the same cannot be said for T-cell lymphomas, a group of aggressive diseases with limited funding and therapeutic advancements.​
​
The Unseen Struggle of T-Cell Lymphomas
While B-cell lymphomas have witnessed significant progress, T-cell lymphomas, particularly the deadly manifestations, remain a formidable challenge. With a myriad of subtypes, research efforts are slow, and treatment options are scarce. Among the rare but highly lethal cases is the spread of T-cell lymphomas to the neurologic system, a devastating complication with limited therapeutic avenues.​
​
Challenges We Face
Several factors hinder the progress in T-cell lymphoma research. The vast array of T-cell lymphoma types, coupled with the scarcity of cases globally, presents a unique challenge. Moreover, inadequate funding opportunities have impeded substantive and innovative breakthroughs. It is time to confront these challenges head-on and pave the way for a brighter future.
​​​
​Transforming Lives Affected by T-Cell Lymphomas
​​Representation and Equity
We strive to enhance representation from minority populations within T-cell lymphoma research. By addressing relevant questions, we aim to reduce disparities in care and ensure that every patient, irrespective of their background, receives the attention and resources they deserve.​
​
Research Funds for Understanding Biology
We are committed to providing essential research funds to develop studies that delve into the intricate biology of T-cell lymphomas. Our focus extends beyond the disease itself, exploring the roles of environmental, lifestyle, and cultural factors in shaping variations in T-cell lymphoma incidences across diverse populations.​
​
Engaging the Research Community
Collaboration is the cornerstone of progress. We actively engage with the research community to bring cutting-edge tools and methodologies to the forefront. By fostering collaboration and innovation, we strive to improve therapies and outcomes for T-cell lymphoma patients—a population with a high unmet need.
